Otsuka (OTCMKTS:OTSKY) Reaches New 1-Year High - Should You Buy?

Key Points

• Otsuka ADR hit a new 52-week high — shares traded as high as $35.1699 and were last at $33.92, up about 5.6% on the session (volume ~25,855), trading above its 50‑day ($30.86) and 200‑day ($28.88) moving averages.
• Analyst sentiment is mixed-to-negative with one Buy, one Hold and two Sell ratings and an average rating of "Reduce"; notable recent moves include downgrades from Goldman Sachs and Zacks to "strong sell" while Morgan Stanley upgraded to "overweight".

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $35.1699 and last traded at $33.92, with a volume of 25855 shares traded. The stock had previously closed at $31.66.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OTSKY. The Goldman Sachs Group downgraded Otsuka from a "strong-buy" rating to a "strong sell" rating in a research report on Friday, February 27th. Zacks Research lowered Otsuka from a "hold" rating to a "strong sell" rating in a research note on Monday, March 2nd. Morgan Stanley upgraded shares of Otsuka to an "overweight" rating in a research note on Friday, January 23rd. Finally, UBS Group raised shares of Otsuka to a "hold" rating in a report on Tuesday, January 27th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Otsuka presently has an average rating of "Reduce".

Otsuka Trading Up 5.6%

The company's 50-day moving average is $30.86 and its 200 day moving average is $28.88.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm's core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.